Skip to main content
. 2020 Aug 14;10:1424. doi: 10.3389/fonc.2020.01424

Figure 5.

Figure 5

Dose and response curves of PC9 and PC9GR cells to Dasatinib, plurpotin, trametinib, and KPT-185. PC9 and PC9GR cell are treated with Dasatinib (A), plurpotin (B), trametinib (C), and KPT-185 (D) at doubling dose for 72 h. Cell viability (y-axis) is detected by CCK-8 assay. KPT-185 is the strongest inhibitor for both PC9 and PC9GR with IC50 0.016 and 0.017, respectively.